Mifepristone: Antineoplastic studies

Oliver Sartor*, William D. Figg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Emerging research suggests that mifepristone may have significant clinical applications in the treatment of certain neoplastic disorders. For example, in vitro studies have shown that RU-486 can inhibit or stimulate--depending on the cell line and the hormonal milieu of the culture medium--the growth of breast cancer cells. In hormone-sensitive breast cancer, anti-tumor activity is maximized by treatment with a combination of RU-486 and estrogen antagonists such as tamoxifen or luteinizing hormone releasing hormone analogues. The few studies of RU-486 administration in women with advanced breast cancer that had failed to respond to tamoxifen have demonstrated short-term disease stabilization (e.g., 5-10 months). This research has suggested that progesterone receptors are necessary but not sufficient for anti-tumor responses. Also promising, although untested in a large-scale study, is use of RU-486 in women with progressive recurrent and/or unresectable benign meningiomas. In addition, RU-486 has inhibited hormone-insensitive human prostate cancer cell lines grown in vitro and in nude mice xenografts.

Original languageEnglish
Pages (from-to)498-505
Number of pages8
JournalClinical Obstetrics and Gynecology
Volume39
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Dive into the research topics of 'Mifepristone: Antineoplastic studies'. Together they form a unique fingerprint.

Cite this